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Supplementary Figure S1 
 
 
Fig. S1: Brightfield (20X) images showing morphological features of PTECs. N and T2D-PTECs images 
were taken 5 days after seeding (Passage 2, seeding density 50,000 cells in 10cm dish). N-T and T2D-T 














Supplementary Figure S2 
 
 
Fig. S2: A) Workflow for RNA-seq and differential expression analysis in PTECs. B) Volcano plot 
showing DEGs in T2D vs N-PTECs. Grey (non-significant fold change), green (fold change more than 2 
and p-value greater than 0.05), blue (fold change less than 2 and p-value lesser than 0.05), and pink (fold 

























Supplementary Figure S3 
 
Fig. S3: A) Genome browser shots showing expression of a few TAGs (SCCN1A, SLC16A5, and CLDN11) 
in N-PTECs (black) and T2D-PTECs (green), as observed in RNA-seq. B) Pie chart showing overlap of 
current study with published DKD studies (1-3). Dark blue color in the pie chart shows that 59 of our 
differentially expressed TAGs also show differential expression in at least one of the three published 
studies. Light blue color shows that 14 TAGs in our study are also differentially expressed in any two of 
the three studies while magenta color shows that 7 TAGs are differentially expressed in all three published 
DKD studies and our study. 23 TAGs, highlighted in brown, show differential expression only in our study. 
We identified differential TAGs in published DKD studies from patient samples and identified overlapping 













Fig. S4: Gene expression profiles of PTECs. A) Bar plot showing number of DEGs in T2D-T vs T2D 
(magenta), N-T vs N (blue), and T2D vs N (Brown). B) Venn diagram showing number of overlapping 
differential TAGs in various comparisons. in T2D-T vs T2D (magenta), N-T vs N (blue), and T2D vs N 
(Brown). C) Violin plots showing fold changes of TAGs in T2D-T vs T2D, N-T vs N, and T2D vs N based 
on RNA-seq (p-adjusted < 0.05). Each dot represent a single TAG and error bars represent minimum and 











Fig. S5: DNA methylation profiles of PTECs. A) Manhattan plot showing differentially methylated probes 
(DMPs, FDR <0.05) in T2D-PTECs as compared to N-PTECs. A few top hits are highlighted. B) Violin 
plot showing distribution of DMPs with at least 20% fold change. C) Bar plot showing genomic 
distribution of DMPs in T2D. D) Stacked bar plot with number of differentially methylated regions 
(DMRs) in T2D-T (96 hours) v T (grey), T2D vs N (clear) and overlapping between T2D-T (96 hours) vs 




























































Fig. S7: Pseudo-color heat map showing mitochondrial function associated DEGs and corresponding d-
ATAC (differential ATAC peaks) and DMP/DMR within 50kb of their TSS. Mitochondrial function 
associated genes are identified as described in the mitochondria associated database (4). Orange color 
represents down regulation of gene expression, hypomethylation, and decreased ATAC peaks while purple 





Supplementary Figure S8 
 
Fig. S8: Potential regulation of TAGs via epigenetic memory. A-C) Altered gene expression (A), 
methylation (B), and chromatin accessibility using ATAC (C) of candidate TAGs SLC16A5 and SLC7A7. 
Gene expression is measured by RNA-seq, fold change (FC) calculated by DESeq2, delta-beta (Δβ) values 
for methylation are calculated using ChAMP package, and differential ATAC-seq fold change (FC) is 














Fig. S9: HNF4A as a potential regulator for candidate TAGs. A) Bar plot showing cell viability after 5-
azacytidine (5-aza) treatment in N and T2D-PTECs. B) Altered methylation levels of HNF4A promoter in 
T2D, N-T, and T2D-T cells. C) Variation in HNF4A gene expression in T2D, N-T, and T2D-T cells. D) 
Variation in HNF4A protein expression in T2D, N-T, and T2D-T cells before and after 5-aza treatment. E) 
Variation in methylation levels of representative TAGs based on EPIC array analysis. All the data shown 
has p-value <0.05 based on EPIC-array analysis. Bars represent average variation in gene expression or 









Supplementary Table S1: Characteristics of human renal PTECs used in the study 
N: = Healthy control; T2D: Type 2 Diabetes 
PTECs from non-diabetic (control, N) and diabetic (T2D) individuals were cultured in renal epithelial 
growth media (REGM, Lonza, NJ, USA), which contains 7 mmol/L glucose as per manufacturer’s 
formulation. These PTECs were from two donors each for N [Lonza, CC-2553, lot nos. 0000530068 (Male) 
and 0000442212 (Female)] and T2D [Lonza, CC-2925, 0000231627 (Male), 0000238893 (Female)].  
Donor 
group 
Age Gender Ethnicity Characteristics Anti-diabetic Drugs 
N 57 M Caucasian No diabetes or 
renal disease 
None 
N 60 F African-
American 
No diabetes or 
renal disease 
None 
T2D 69 M Caucasian diabetes 
Metformin,  
Furosemide 




Supplementary Table S2. List of primers used in the study for gene expression, methylation 
and ChIP-qPCR. 
 
Gene Expression qPCR 
Symbol Primer Sequence 
CLDN3 Forward Primer CCAAGGCCAAGATCACCAT 
CLDN3 Reverse Primer GGTTGTAGAAGTCCCGGATAATG 
CLDN4 Forward Primer GCCTTACTCCGCCAAGTATT 
CLDN4 Reverse Primer AGGGAAGAACAAAGCAGAGAG 
CLDN8 Forward Primer GCTTCCGTGATGTCCTTCTT 
CLDN8 Reverse Primer GAGCCTTCACCTTCTCATTGT 
CLDN10 Forward Primer AGACACAGGCTTCTTCCTAGA 
CLDN10 Reverse Primer GAGTGAGACAGGACATGAAAGG 
CLDN11 Forward Primer CGAACTCCTGGACTCAAAGTATC 
CLDN11 Reverse Primer GGCTCCCATTGTCATCTGTATC 
CLDN14 Forward Primer GCTCCGGAAGAACTTTCAGATA 
CLDN14 Reverse Primer GTTCTTGACTTCTTGGCTTGTG 
CLDN16 Forward Primer CCCTGATGAGCCGTACATTAAA 
CLDN16 Reverse Primer CATACCACACAGAGCCAATGA 
COL6A2 Forward Primer CAACAACTGCCCAGAGAAGA 
COL6A2 Reverse Primer CATGTGGAAGAGCAGGATGT 
CTCF Forward Primer TACAAACACACCCACGAGAAG 
CTCF Reverse Primer CTCCAGTATGAGAGCGAATGTG 
GAPDH Forward Primer GGTGTGAACCATGAGAAGTATGA 
GAPDH Reverse Primer GAGTCCTTCCACGATACCAAAG 




HNF4A Reverse Primer TAAGACAGTGCCTGGGAGTA 
KCNQ1 Forward Primer GAAGCCCTCACTGTTCATCTC 
KCNQ1 Reverse Primer GCGTCACCTTGTCTTCTACTC 
LY75 Forward Primer GAAAGGAGGCTCAGAGGAAAG 
LY75 Reverse Primer GCCAGGTCCCATCAATTAAGA 
RIPK4 Forward Primer TATGTGTGGCCAGCTCTTAAC 
RIPK4 Reverse Primer GAAACGAACGGCAGCTAGTA 
SCNN1A Forward Primer GGCTGTGCCTACATCTTCTATC 
SCNN1A Reverse Primer GAGAAGTCAACCTGGAGCTTATAG 
SLC2A1 Forward Primer GGACAGGCTCAAAGAGGTTATG 
SLC2A1 Reverse Primer AGGAGGTGGGTGGAGTTAAT 
SLC5A2 Forward Primer CGGTACAGACCTTCGTCATTC 
SLC5A2 Reverse Primer CTCCCAGGTATTTGTCGAAGAG 
SLC14A1 Forward Primer CACTTTGGGAGATGGAGGTAAA 
SLC14A1 Reverse Primer GCTACACCTGGCTAATGTTACT 
SLC14A2 Forward Primer GCCCTTTGACTCCATCTACTT 
SLC14A2 Reverse Primer GACGTAGAACATGCCTCCTATC 
SLC16A2 Forward Primer CTACCATGTGGCCTTCTACTTT 
SLC16A2 Reverse Primer GCTGGAATCTCTCTGCTCTTT 
SLC16A5 Forward Primer CTACATGTCCAGCTTCTTCCTC 
SLC16A5 Reverse Primer CTTGCCTTGCTCCTTCTTCT 
SLC34A1 Forward Primer ACTAGGATAGGCAGGAGTAAGG 
SLC34A1 Reverse Primer GCAAGGAGGTGTGCAAATTC 
SLC47A1 Forward Primer ACCGTTTCCCTGCTGATTAC 




SLCO1A2 Forward Primer GTCTACTCCTTACTCTCCTTCCT 
SLCO1A2 Reverse Primer CACCCTTCCTTACTCCATTCTC 
SPARC Forward Primer GGGAGTGTATGGTTCCTGTAAG 
SPARC Reverse Primer GCTCAGTCTGGTGCTGATAAT 
TGFB1 Forward Primer CCTGCCTGTCTGCACTATTC 
TGFB1 Reverse Primer TGCCCAAGGTGCTCAATAAA 
TUBB Forward Primer GGGAGGTGTCAGCAGTATTATC 
TUBB Reverse Primer GAGGTAGAGTTGGAAAGGGAAG 
      
ChIP qPCR 
CLDN10 Forward Primer CCGTGTCCTTGTTCTCTCATT 
CLDN10 Reverse Primer TCATCCCTTCATTGCTGTCTC 
CLDN14 Forward Primer TCCCAAAGTGCAGGGATTAC 
CLDN14 Reverse Primer GAACAGGGAAGTGGTGAATGA 
CLDN16 Forward Primer CAAGGGCTCTCAGACCATAAAT 
CLDN16 Reverse Primer CCTAACCTTTCAGCATCGTAGAG 
LY75 Forward Primer GGCCACCTCAAGTACACATTA 
LY75 Reverse Primer CTTCCTGTGGACACTGCTATC 
SLC16A2 Forward Primer AGGGCAGGAGAACAGGATA 
SLC16A2 Reverse Primer CTCCCTTCCCAAACTACTGAAC 
SCL16A5 Forward Primer CTGAGTATACAGGGTGTGGTTG 
SCL16A5 Reverse Primer GATCTGTGGACGATGGAGTTT 
   
Methylation qPCR   
CLDN10 Forward Primer Qiagen, GPH1003703 











PTEC No. of overlapping peaks % Overlap 
N 120,412 56 
T2D 118,872 48 
N-T 135,309 52 
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